Micrometastatic Cancer Cells in Lymph Nodes, Bone Marrow, and Blood Clinical Significance and Biologic Implications

被引:64
作者
Leong, Stanley P. L. [1 ,2 ,3 ]
Tseng, William W. [4 ]
机构
[1] Calif Pacific Med Ctr, Ctr Melanoma Res & Treatment, Melanoma Program, San Francisco, CA 94115 USA
[2] Sutter Pacific Med Fdn, San Francisco, CA 94115 USA
[3] Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94115 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Surg, Houston, TX 77030 USA
关键词
cancer metastasis; CIRCULATING TUMOR-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; AMERICAN JOINT COMMITTEE; BREAST-CANCER; SENTINEL-NODE; MELANOMA PATIENTS; METASTATIC MELANOMA; PROGNOSTIC-SIGNIFICANCE; FREE SURVIVAL; MOLECULAR-DETECTION;
D O I
10.3322/caac.21217
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer metastasis may be regarded as a progressive process from its inception in the primary tumor microenvironment to distant sites by way of the lymphovascular system. Although this type of tumor dissemination often occurs in an orderly fashion via the sentinel lymph node ( SLN), acting as a possible gateway to the regional lymph nodes, bone marrow, and peripheral blood and ultimately to distant metastatic sites, this is not a general rule as tumor cells may enter the blood and spread to distant sites, bypassing the SLN. Methods of detecting micrometastatic cancer cells in the SLN, bone marrow, and peripheral blood of patients have been established. Patients with cancer cells in their SLN, bone marrow, or peripheral blood have worse clinical outcomes than patients with no evidence of spread to these compartments. The presence of these cells also has important biologic implications for disease progression and the clinician's understanding of the process of cancer metastasis. Further characterization of these micrometastatic cancer cells at each stage and site of metastasis is needed to design novel selective therapies for a more "personalized" treatment. (C) 2014 American Cancer Society.
引用
收藏
页码:196 / 206
页数:11
相关论文
共 119 条
[11]   Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer.: Comparison of CK19, MUC1 and CEA using RT-PCR [J].
Berois, N ;
Varangot, M ;
Aizen, B ;
Estrugo, R ;
Zarantonelli, L ;
Fernández, P ;
Krygier, G ;
Simonet, F ;
Barrios, E ;
Musé, L ;
Osinaga, E .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (06) :717-723
[12]   Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials [J].
Bidard, Francois-Clement ;
Fehm, Tanja ;
Ignatiadis, Michail ;
Smerage, Jeffrey B. ;
Alix-Panabieres, Catherine ;
Janni, Wolfgang ;
Messina, Carlo ;
Paoletti, Costanza ;
Mueller, Volkmar ;
Hayes, Daniel F. ;
Piccart, Martine ;
Pierga, Jean-Yves .
CANCER AND METASTASIS REVIEWS, 2013, 32 (1-2) :179-188
[13]   Sentinel Lymph Node Biopsy in Melanoma [J].
Boland, Genevieve M. ;
Gershenwald, Jeffrey E. .
CANCER JOURNAL, 2012, 18 (02) :185-191
[14]   A pooled analysis of bone marrow micrometastasis in breast cancer [J].
Braun, S ;
Vogl, FD ;
Naume, B ;
Janni, W ;
Osborne, MP ;
Coombes, RC ;
Schlimok, G ;
Diel, IJ ;
Gerber, B ;
Gebauer, G ;
Pierga, JY ;
Marth, C ;
Oruzio, D ;
Wiedswang, G ;
Solomayer, EF ;
Kundt, G ;
Strobl, B ;
Fehm, T ;
Wong, GYC ;
Bliss, J ;
Vincent-Salomon, A ;
Pantel, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (08) :793-802
[15]   The amount of metastatic melanoma in a sentinel lymph node: Does it have prognostic significance? [J].
Carlson, GW ;
Murray, DR ;
Lyles, RH ;
Staley, CA ;
Hestley, A ;
Cohen, C .
ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (05) :575-581
[16]   Nodal nevi and cutaneous melanomas [J].
Carson, KF ;
Wen, DR ;
Li, PX ;
Lana, AMA ;
Bailly, C ;
Morton, DL ;
Cochran, AJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (07) :834-840
[17]   Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies [J].
Chia, SK ;
Speers, CH ;
Bryce, CJ ;
Hayes, MM ;
Olivotto, IA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1630-1637
[18]   Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node [J].
Cochran, AJ ;
Wen, DR ;
Huang, RR ;
Wang, HJ ;
Elashoff, R ;
Morton, DL .
MODERN PATHOLOGY, 2004, 17 (07) :747-755
[19]   Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer [J].
Cohen, Steven J. ;
Punt, Cornelis J. A. ;
Iannotti, Nicholas ;
Saidman, Bruce H. ;
Sabbath, Kert D. ;
Gabrail, Nashat Y. ;
Picus, Joel ;
Morse, Michael ;
Mitchell, Edith ;
Miller, M. Craig ;
Doyle, Gerald V. ;
Tissing, Henk ;
Terstappen, Leon W. M. M. ;
Meropol, Neal J. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) :3213-3221
[20]  
Collaborative Ocular Melanoma Study Group, 2001, Arch Ophthalmol, V119, P670